NeuroSense joins open innovation consortium EverythingALS; Ready to enroll US and European patients in a phase IIb study

NeuroSense is currently enrolling patients in PARADIGM, a double-blind, placebo-controlled, multicenter Phase IIb clinical trial to evaluate its lead ALS drug candidate, PrimeC, in Israel and expects to begin patient enrollment in the US and EU this quarter. First results are expected in the second quarter of 2023. PrimeC was tested in a Phase IIa clinical study which successfully met its safety and efficacy criteria, including reduction of functional and respiratory deterioration, and demonstrated statistically significant changes in ALS-related biomarkers.

In addition to providing financial support for ongoing research projects, NeuroSense’s strategic collaboration with EverythingALS will provide insight into patient needs and enable the company to better serve the ALS community.

We are thrilled to be working with NeuroSense Therapeutics,” said Indu Navar, Founder of the Peter Cohen Foundation, operating as EverythingALS. “EverythingALS and NeuroSense are taking similar actions in the fight against neurological diseases, including conducting extensive biomarker research. NeuroSense’s innovative therapeutic approach addresses this complex disease from multiple angles. Collaboration is key to making giant strides towards digital biomarkers for use in clinical trials. of ALS, and to ultimately work towards the discovery of a potential cure.”

“At NeuroSense, our daily motivation stems from patients and their loved ones, which translates into a patient-centric approach to drug development,” said Nedira Salzman-Frenkel, Vice President of Business Development at NeuroSense. “An alliance with EverythingALS, an organization with shared values, supports our mission to develop disease-modifying therapy. Together, we aim to advance research into biological markers of disease and deepen the scientific community’s understanding of the underlying causes.”

Alon Ben NoonNeuroSense CEO to present to EverythingALS ALS Expert Series the August 3, 2022 at 4pm PT/7 p.m. ET. In his presentation titled “NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study,” Dr. Well noon will review the latest clinical and biomarker data on the efficacy of PrimeC in ALS. “As we prepare to enroll patients in the US and EU for our Phase IIb PARADIGM study, we are strengthening our engagement with the international ALS community,” added Mr. Well noon.

To listen to Mr. Ben-Noon’s presentation, register here: LINK

About ALS

According Medicine Johns Hopkinsamyotrophic lateral sclerosis (ALS) affects up to 30,000 people in United States, with 5,000 new cases diagnosed each year. ALS is a difficult disease to diagnose because there is no one test or procedure to ultimately establish the diagnosis of the disease and it can take 12 to 18 months to diagnose by method of elimination. There is also no known cure for ALS and many clinical trials to find treatments are currently underway.

About EverythingALS

EverythingALS is a patient-focused nonprofit, part of the Peter Cohen Foundation, a 501(3)c organization, bringing technological innovations and data science to support efforts – from care to cure – for people with ALS, offering a data-driven platform for direct engagement with patients, caregivers, researchers and pharmaceutical companies. For more information, please visit

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on the discovery and development of treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the greatest unmet medical needs of our time, with treatment options limited efficacy for patients to date. Due to the complexity of neurodegenerative diseases and based on sound scientific research on a broad panel of related biomarkers, NeuroSense’s strategy is to develop combination therapies targeting multiple pathways associated with these diseases.

For more information, we invite you to visit our website and follow us on LinkedIn and Twitter.

Forward-looking statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements in this press release can be identified by the use of words such as “anticipate”, “believe”, “intend”, “could”, “estimate”, “expect”, “have the ‘intent to’, ‘seek,’ ‘may’, ‘could’, ‘plan’, ‘potential’, ‘predict’, ‘project’, ‘target’, ‘aim’, ‘should’, ‘will’, ‘ would” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to uncertainties, risks and inherent assumptions that are difficult to predict and include statements regarding the company’s PrimeC development program; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the timing of current and future clinical trials; the nature, strategy and direction of the en treprise and other updates thereto; and the development and commercial potential of any of the Company’s product candidates. In addition, certain forward-looking statements are based on assumptions about future events which may not prove to be accurate. The forward-looking statements contained in this announcement are made as of this date, and NeuroSense Therapeutics Ltd. assumes no obligation to update this information, except as required by applicable law.


SOURCE NeuroSense; AllALS

Comments are closed.